China’s Antibody Drug Conjugate R&D & Pharmaceutical Companies’ Competencies – 27 July 2021

  • Private Equity
  • Healthcare
  • Greater China


Executive at Suzhou MediLink Therapeutics Ltd


  • Antibody drug conjugate (ADC) R&D barriers – linker technologies, antibody design, cytotoxic payload and conjugation process, plus domestic and foreign pharmaceutical companies’ technology platforms
  • Clinical research challenges, plus China's Center for Drug Evaluation and the US Food and Drug Administration review and approval
  • Anti-TROP-2 and anti-HER2 ADC clinical research progress at home and abroad, plus clinical data analysis
  • R&D team demand and personnel structure, plus domestic and foreign pharmaceutical companies’ team competency comparison


Gain access to Premium Content

Submit your details to access up to 5 Forum Transcripts or to request a complimentary one week trial.

    One week, unlimited access to over 40,000 transcripts
The information, material and content contained in this transcript (“Content”) is for information purposes only and does not constitute advice of any type or a trade recommendation and should not form the basis of any investment decision.This transcript has been edited by Third Bridge for ease of reading. Third Bridge Group Limited and its affiliates (together “Third Bridge”) make no representation and accept no liability for the Contentor for any errors, omissions or inaccuracies in respect of it. The views of the specialist expressed in the Content are those of the specialist and they are not endorsed by, nor do they represent the opinion of, Third Bridge. Third Bridge reserves all copyright, intellectual and other property rights in the Content. Any modification, reformatting, copying, displaying, distributing, transmitting, publishing, licensing, creating derivative works from, transferring or selling any Content is strictly prohibited